Promising results from the Phase 2 study of novel extended-release ketamine tablets (R-107) for Treatment-Resistant Depression accepted for publication by Nature Medicine

Posted on by

AUCKLAND, New Zealand, June 24, 2024 /PRNewswire/ — Douglas Pharmaceuticals, New Zealand’s largest pharmaceutical company, is pleased to announce that results from their recent trial, “Randomised Placebo-Controlled Phase 2 Study of Extended-Release Ketamine Tablets (R-107) for…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.